Pulmonary FABP4 is an inverse biomarker of pneumonia in critically ill children and adults - Lydon, Emily C.; Van Phan, Hoang; Mick, Eran; Spottiswoode, Natasha; Calfee, Carolyn S.; Mourani, Peter M.; Langelier, Charles R. (medRxiv, 2024)
Lower respiratory tract infection (LRTI) is a leading cause of mortality, yet accurate diagnosis remains challenging. We studied two prospective observational cohorts of critically ill patients with acute respiratory failure (pediatric, N=261; adult N=202) and analyzed RNA sequencing data from tracheal aspirate collected following intubation. Patients with LRTI or non-infectious acute respiratory failure were adjudicated by a multi-physician team. We found that FABP4 expression was significantly downregulated in children with confirmed LRTI compared to those with non-infectious respiratory failure, and when incorporated into a diagnostic classifier, achieved an area under the receiver operating characteristic curve (AUC) of 0.90±0.07. When tested in the adult cohort, and AUC of 0.85±0.12 was attained. These findings suggest that pulmonary FABP4 could serve as a valuable biomarker for the early diagnosis of LRTI in critically ill patients across the age spectrum, offering a potential tool for improving clinical outcomes and reducing unnecessary antibiotic use.Competing Interest StatementThe authors have declared no competing interest.Funding Statement5R01HL155418 (CRL, PMM); Chan Zuckerberg Biohub San Francisco (CRL); R35HL140026 (CSC); R01HL124103 (PMM)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The pediatric cohort study was approved by the Collaborative Pediatric Critical Care Research IRB at the University of Utah (protocol #00088656). Informed consent was obtained from parents or other legal guardians. The adult cohort was approved by the University of California Institutional Review Board (protocol #10-02701) and informed consent was obtained from patients or surrogate decision makers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data, code, and results are available at: https://github.com/infectiousdisease-langelier-lab/LRTI_FABP4_classifier for reviewing and reproducing the analyses. https://github.com/infectiousdisease-langelier-lab/LRTI_FABP4_classifier